2025年3月19日 · Earlier results from the phase 3 EMPOWER-Lung 1 trial demonstrated significant survival benefits and a generally acceptable safety profile of first-line cemiplimab …

Lung 1 Chinese Name : Zhongfu (English translation: Central Palace) Location: On the upper lateral chest, 1 cun below LU 2, level in the first intercostal space, 6 cun from the midline of the …

2018年10月25日 · Middle Palace (Lung 1) Entry point of the Lung Channel and window of the sky point. Physical Level. Emotional/Mental. Spirit Level. Location: On the chest, level with the …

EMPOWER-Lung 1 is a multicentre, open-label, global, phase 3 randomised, controlled trial of cemiplimab monotherapy versus investigator's choice of platinum-doublet chemotherapy in the …

2020年9月23日 · EMPOWER-Lung 1研究是一项开放标签、随机、多中心的III期试验，纳入710例不适合手术切除或现有放化疗方案、在接受现有放化疗方案后进展的局部晚期IIIB/C期NSCLC …

2025年3月18日 · Earlier results from the phase 3 EMPOWER-Lung 1 trial demonstrated significant survival benefits and a generally acceptable safety profile of first-line cemiplimab …

2021年2月13日 · Background: We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed …

6 天之前 · The EMPOWER-Lung 1 trial is a landmark phase 3 study evaluating cemiplimab, a PD-1 inhibitor, as a first-line monotherapy for patients with advanced non-small cell lung cancer …

2025年2月27日 · Interstitial lung disease, a TRAE of special interest with deruxtecan-containing ADC, 16 occurred in 8.8% of patients with datopotamab deruxtecan and 4.1% with docetaxel. …

2024年10月1日 · Improved activity of cemiplimab was observed in patients with PD-L1 ≥90%: medianOS was 38.8 m (22.9, NE), median PFS was 14.7 m (10.2, 21.1), ORR was 60.6% …